Median overall survival for patients diagnosed with IDH-mutant astrocytoma ranges between 7 and 10 years, depending on various factors such as patient age, tumour location, tumour grade, and the specific treatment protocol undertaken [1,14,15,16]. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).